Fluidigm Withdraws IPO Registration | GenomeWeb
NEW YORK (GenomeWeb News) – Fluidigm has decided to the pull the plug on its proposed initial public offering “due to the historic instability in the market,” the firm said today.
 
The South San Francisco-based company had expected to offer 5.3 million shares of common stock at a price of between $14 and $16 per share. It had expected to raise net proceeds of between $70.8 million and $81.9 million from the offering, which was to fund sales and marketing initiatives, R&D activities, and facilities and manufacturing expansion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.